Losing just 1 kilogram (about 2.2 pounds) of body weight while taking GLP-1 diabetes drugs is linked to a 7% lower chance of having a heart attack, stroke, or dying from heart disease.

Pro

Against

Evidence from Studies

Supporting (1)

Community contributions welcome

Association Between the Magnitude of Glycemic Control and Body Weight Loss With GLP-1 Receptor Agonists and Risk of Atherosclerotic Cardiovascular Disease: A Systematic Review and Meta-analyses of Randomized Diabetes Cardiovascular Outcomes Trials

Systematic Review With Meta-Analysis

Human

2025 Apr

Contradicting (0)

Community contributions welcome

No contradicting evidence found

Gold Standard Evidence Needed

According to GRADE and EBM methodology, here is what ideal scientific evidence would look like to definitively prove or disprove this specific claim, ordered from strongest to weakest evidence.

Source Study

Association Between the Magnitude of Glycemic Control and Body Weight Loss With GLP-1 Receptor Agonists and Risk of Atherosclerotic Cardiovascular Disease: A Systematic Review and Meta-analyses of Randomized Diabetes Cardiovascular Outcomes Trials

Score: 48

DOI: 10.1007/s10557-024-07547-3

Similar Assertions

GLP-1 diabetes drugs that lower blood sugar and weight the most tend to offer the biggest protection against heart attacks and strokes in people with type 2 diabetes.

92%

For people with type 2 diabetes, lowering their blood sugar by 1% using certain diabetes medications is linked to a 25% lower chance of having a heart attack, stroke, or dying from heart disease.

86%

For people with type 2 diabetes, lowering their blood pressure or bad cholesterol with GLP-1 drugs doesn't seem to make a noticeable difference in their risk of heart attack or stroke.

85%

GLP-1 diabetes drugs help prevent heart attacks and strokes mainly by lowering blood sugar and helping people lose weight—not by lowering blood pressure or bad cholesterol.

84%

Among adults with type 2 diabetes starting injectable treatment, those using GLP-1 receptor agonists had a lower risk of heart attack, stroke, or death over two years compared to those using basal insulin, based on statistical analysis of patient data.

83%